Analyst Ratings For ACADIA Pharmaceuticals (NASDAQ:ACAD)
Today, Ladenburg Thalmann Financial Services reiterated its Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a price target of $50.00.
There are 3 hold ratings, 9 buy ratings on the stock.
The current consensus rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) is Buy (Score: 2.75) with a consensus target price of $44.33 per share, a potential 15.36% upside.
Some recent analyst ratings include
- 10/2/2017-Ladenburg Thalmann Financial Services Reiterated Rating of Buy.
- 9/17/2017-Needham & Company LLC Reiterated Rating of Buy.
- 8/10/2017-Cowen and Company Reiterated Rating of Outperform.
- 8/9/2017-HC Wainwright Reiterated Rating of Buy.
- 5/22/2017-Rodman & Renshaw Reiterated Rating of Buy.
- 4/12/2017-Jefferies Group LLC Reiterated Rating of Buy.
Recent Insider Trading Activity For ACADIA Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD) has insider ownership of 22.25% and institutional ownership of 97.10%.
- On 8/30/2017 Glenn Baity, EVP, sold 26,507 with an average share price of $34.87 per share and the total transaction amounting to $924,299.09. View SEC Filing
- On 8/9/2017 Glenn Baity, EVP, sold 14,322 with an average share price of $34.88 per share and the total transaction amounting to $499,551.36. View SEC Filing
- On 7/20/2017 Glenn Baity, EVP, sold 38,097 with an average share price of $30.00 per share and the total transaction amounting to $1,142,910.00. View SEC Filing
- On 6/22/2017 Glenn Baity, EVP, sold 1,903 with an average share price of $30.00 per share and the total transaction amounting to $57,090.00. View SEC Filing
- On 2/16/2017 Terrence O. Moore, EVP, sold 157,540 with an average share price of $39.77 per share and the total transaction amounting to $6,265,365.80. View SEC Filing
- On 12/27/2016 Glenn Baity, EVP, sold 9,800 with an average share price of $30.46 per share and the total transaction amounting to $298,508.00. View SEC Filing
- On 12/20/2016 Glenn Baity, EVP, sold 10,000 with an average share price of $30.00 per share and the total transaction amounting to $300,000.00. View SEC Filing
Recent Trading Activity for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Shares of ACADIA Pharmaceuticals closed the previous trading session at with shares trading hands.